Cambridge, UK, 19 June 2020 - OKRA, a leading provider of Artificial Intelligence (AI) driven analytics for Life Sciences, today hit an important milestone, delivering 2 million validated predictions so far in 2020, smashing through its yearly target in just half the expected time. This underscores OKRA’s achievements in empowering the pharmaceutical industry with explainable, real-time AI solutions.
London – Arena International announced today the first-ever Direct-to-Patient and Virtual Clinical Trials (https://arena-international.com/dtpvirtual/) will be held as a Digital Experience on Thursday, 9 July 2020. As COVID-19 has forced the market to move towards decentralized and remote models, this event provides the perfect opportunity for clinical trial professionals to hear, meet and learn from top-class speakers around the world to discuss challenges and innovations in this critical time.
To address the budgeting challenges experienced by global sponsors and CROs during study start-up, Greenphire’s Catherine Click, Director, Clinical Pricing & Analysis, and Kyle Cunningham, Chief Product Officer will be discussing the four key budgeting challenges faced by sponsors and CROs which can hinder global study success in an upcoming webinar on Thursday June 18, 2020 at 2:00pm ET.
Chemspace and ChemAlive (the largest repository of quantum chemical data, a Contract Research Company that develops software products to obtain accurate and reliable data on molecular properties, synthetic reactions, verification of molecules using quantum chemistry), announced the launch of the collaboration to provide accurate molecular structural information about commercial small molecules.
Dr. Elizabeth O’Day will lead personalized medicine investment and adoption efforts globally during three-year term
WALTHAM, Mass., June 9, 2020 — Olaris, a precision medicine company that is working to fundamentally change how diseases are treated, today announced that The Personalized Medicine Coalition (PMC) has elected Olaris CEO and Founder Dr. Elizabeth O’Day to serve a three-year term on the PMC Board of Directors.